This site is intended for healthcare professionals
CDK4/6 inhibitors in breast cancer

Expert opinion

Read time: 40 mins
Last updated:17th Aug 2021

Watch our leading breast cancer experts share their thoughts on:

  • the clinical utility of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer
  • the key considerations when selecting the right CDK4/6 inhibitor for your patient
  • optimal management of patients treated with CDK4/6 inhibitors
  • commentary on the use of CDK4/6 inhibitors in the COVID-19 era

How is risk of recurrence managed in early breast cancer? Explore this topic with our expert-led webinar highlights, discussing important topics in the field including:

  • The evolving treatment landscape in early breast cancer
  • Risk stratification tools in early breast cancer for therapy optimisation
  • Emerging evidence for new strategies in treating high-risk early breast cancer

Join Dr Gregory Vidal, Professor Nadia Harbeck and Professor Stephen Johnston for their expert insights into this rapidly evolving field of medicine.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Roundtable Event 2020: CDK4/6 inhibitors and patient management

In the HR+/HER2- metastatic breast cancer setting, healthcare professionals have moved away from first-line chemotherapy towards CDK4/6 inhibitors (palbociclib, ribociclib and abemaciclib) as the new standard of care. This roundtable discussion event, led by experts Dr Gregory Vidal, Dr Laura Spring, Professor Nadia Harbeck and Dr Veronique Dieras, covers a series of topics related to management of metastatic breast cancer patients treated with CDK4/6 inhibitors in the clinic. It also provides an in-depth look into what the future holds for treatment of early breast cancer using CDK4/6 inhibitors.

Key topics include:

  1. Roundtable introduction
  2. Overview of the three CDK4/6 inhibitors in breast cancer
  3. CDK4/6 inhibitor side effects and treatment monitoring in breast cancer
  4. Side effect management, dose modification and switching treatments for CDK4/6 inhibitors in breast cancer
  5. The future: considerations for managing early breast cancer in patients with CDK4/6 inhibitors – how will this be different?
  6. Summary


Introduction

Expert speakers Dr Gregory Vidal, Dr Laura Spring, Professor Nadia Harbeck and Dr Veronique Dieras introduce themselves and the discussion topics. Topics include clinical data available in both advanced and curative breast cancer settings and optimal management of patients treated with CDK4/6 inhibitors.

Overview of the three CDK4/6 inhibitors in breast cancer

An overview of current clinical trials, treatment response and survival data provide insight into what the future holds for CDK4/6 inhibitors in the advanced setting, and how this might differ in high burden, HER2+ and triple negative breast cancer.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Medical expert interviews

Here, you can find the full medical expert interviews on CDK4/6 inhibitors for treating HR+/HER2- metastatic breast cancer with our breast cancer experts, Dr Gregory Vidal, Dr Laura Spring and Dr Alistair Ring. Whilst you may have spotted some of the clips related to the utility of, and differences between abemaciclib, ribociclib and palbociclib throughout the Learning Zone, there are more unanswered questions to discover in the full-length interview videos below.

Dr Gregory Vidal, MD, PhD

Dr Gregory Vidal, a medical oncologist at the West Cancer Center and Research Institute addresses some key questions on the use of CDK4/6 inhibitors for the treatment of HR+/HER2- metastatic breast cancer. Key discussion points include the safety and monitoring of abemaciclib, palbociclib and ribociclib in clinical practice and emerging investigational biomarkers of CDK4/6 resistance. He also discusses the importance of keeping up to date with the latest data for CDK4/6 inhibitors in treating breast cancer patients, as the field is ever-changing, with many new ongoing clinical trials in different patient settings.

Dr Gregory Vidal also helped to co-create an interactive eLearning module that further highlights the differences between the three CDK4/6 inhibitors; abemaciclib, palbociclib and ribociclib. The eLearning incorporates three patient cases for metastatic breast cancer, where one CDK4/6 inhibitor is better suited to each patient. The rationale for CDK4/6 inhibitor selection in each case is also discussed.

To go through the patient case studies, visit our eLearning module

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Medical expert biographies

Dr Gregory Vidal, MD, PhD

Dr Gregory Vidal.jpgDr Gregory Vidal, MD, PhD, is a Medical Oncologist at West Cancer Center and Research Institute and Assistant Professor at the University of Tennessee Health Science Center. Dr Vidal trained as a clinical researcher at the University of Stanford, taking part in research led by leading medical researchers. The aim of his research then, and now, is to discover and develop safe and effective treatments for breast cancer. Dr Vidal is the recipient of multiple awards and he has authored and co-authored numerous research articles in journals including the New England Journal of Medicine, Lancet Oncology and Nature Communications.

Dr Laura Spring, MD

Dr Laura Spring.jpgDr Laura Spring, MD, is a Medical Oncologist and clinical researcher at the Massachusetts General Hospital Cancer Center and Harvard Medical School. Dr Spring is particularly interested in targeted therapies in the neoadjuvant setting and has conducted multiple breast cancer research trials for localised metastatic breast cancer. She has authored and co-authored multiple research and review articles in journals including Lancet, The Lancet Oncology and Clinical Cancer Research. Dr Spring is also the recipient of the Young Investigator Award from the ASCO Conquer Cancer Foundation for her work on blood-based testing in the neoadjuvant setting using circulating tumour cell (CTC) monitoring.

Dr Alistair Ring, MD, PhD

Dr Alistair Ring.jpgDr Alistair Ring, MD, PhD, is a Consultant Medical Oncologist at The Royal Marsden NHS Trust, and a principle investigator at the Institute of Cancer Research, London, UK. Dr Ring received his medical research degree at the Institute of Cancer in 2005 and his current research interests are in the management of early and metastatic breast cancer patients who are older. In 2018, he was appointed Honorary Reader in Breast Cancer Clinical Trials at the Institute of Cancer Research. He has authored and co-authored many peer-reviewed research articles in journals such as The Lancet Oncology, Cancer Research and the European Journal of Cancer.

Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Welcome: